首页> 外文期刊>World Journal of Vaccines >Transgene IL-21-Engineered T Cell-Based Vaccine Potently Converts CTL Exhaustion via the Activation of the mTORC1 Pathway in Chronic Infection
【24h】

Transgene IL-21-Engineered T Cell-Based Vaccine Potently Converts CTL Exhaustion via the Activation of the mTORC1 Pathway in Chronic Infection

机译:转基因IL-21工程化的基于T细胞的疫苗通过激活mTORC1途径在慢性感染中有效地转化CTL衰竭。

获取原文
       

摘要

CD8~(+) cytotoxic T lymphocyte (CTL) exhaustion is one of the major obstacles for the effectiveness of virus control in chronic infectious diseases. We previously generated novel ovalbumin (OVA)-specific 41BBL-expressing OVA-T_(EXO) and human immunodeficiency virus (HIV-1) Gag-specific Gag-T_(EXO) vaccines, inducing therapeutic immunity in wild-type C57BL/6 (B6) mice, and converting CTL exhaustion in recombinant OVA-specific adenovirus AdV_(OVA)-infected B6 (AdV_(OVA)-B6) mice with chronic infection. IL-21 cytokine plays an important role in controlling chronic infections. Therefore, in this study, we constructed recombinant transgene IL-21-expressing AdV_(IL-21), and generated IL-21-expressing OVA-T_(EXO/IL-21) and Gag-T_(EXO/IL21) vaccines, or control vaccines (OVA-T_(EXO/Null) and Gag-T_(EXO/Null)) by infecting OVA-T_(EXO )and Gag-T_(EXO) cells with AdV_(IL-21) or the control AdV_(Null), lacking transgene, and assessed their effects in B6 or AdV_(OVA)-B6 mice. We demonstrate that both OVA-T_(EXO/IL-21) and control OVA-T_(EXO/Null )vaccines are capable of converting CTL exhaustion in chronic infection. However, the OVA-T_(EXO/IL-21) vaccine more efficiently rescues exhausted CTLs by increasing stronger CTL proliferation and effector cytokine IFN- γ expression than the control OVA-T_(EXO/Null )vaccine in AdV_(OVA)-B6 mice with chronic infection, though both vaccines stimulated comparable OVA-specific CTL responses and protective immunity against OVA-expressing BL6-10_(OVA) melanoma lung metastasis in wild-type B6 mice. In vivo , the OVA-T_(EXO/IL-21)-stimulated CTLs more efficiently up-regulate phosphorylation of mTORC1-controlled EIF4E and expression of mTORC1- regulated T-bet molecule than the control OVA-T_(EXO/Null)-stimulated ones. Importantly, the Gag-T_(EXO/IL21) vaccine induces stronger Gag-specific therapeutic immunity against established Gag-expressing BL6-10_(Gag) melanoma lung metastases than the control Gag-T_(EXO/Null )vaccine in chronic infection. Therefore, this study should have a strong impact on developing new therapeutic vaccines for patients with chronic infections.
机译:CD8〜(+)细胞毒性T淋巴细胞(CTL)耗尽是在慢性传染病中有效控制病毒的主要障碍之一。我们先前产生了新型卵白蛋白(OVA)特异性表达的OVA-T_(EXO)和人类免疫缺陷病毒(HIV-1)Gag特异性Gag-T_(EXO)疫苗,在野生型C57BL / 6( B6)小鼠,并在慢性感染的重组OVA特异性腺病毒AdV_(OVA)感染的B6(AdV_(OVA)-B6)小鼠中转化CTL耗尽。 IL-21细胞因子在控制慢性感染中起重要作用。因此,在这项研究中,我们构建了表达IL-21的重组转基因AdV_(IL-21),并生成了表达IL-21的OVA-T_(EXO / IL-21)和Gag-T_(EXO / IL21)疫苗,通过用AdV_(IL-21)或对照AdV_()感染OVA-T_(EXO)和Gag-T_(EXO)细胞来感染或控制疫苗(OVA-T_(EXO / Null)和Gag-T_(EXO / Null)) Null),缺少转基因,并评估了它们在B6或AdV_(OVA)-B6小鼠中的作用。我们证明OVA-T_(EXO / IL-21)和对照OVA-T_(EXO / Null)疫苗都能够在慢性感染中转化CTL衰竭。但是,与AdV_(OVA)-B6中的对照OVA-T_(EXO / Null)疫苗相比,OVA-T_(EXO / IL-21)疫苗通过增加更强的CTL增殖和效应细胞因子IFN-γ表达,更有效地拯救了疲惫的CTL。慢性感染的小鼠,尽管两种疫苗在野生型B6小鼠中均能刺激类似的OVA特异性CTL反应和针对表达OVA的BL6-10_(OVA)黑色素瘤肺转移的保护性免疫。在体内,与对照OVA-T_(EXO / Null)-相比,OVA-T_(EXO / IL-21)刺激的CTL更有效地上调mTORC1调控的EIF4E的磷酸化和mTORC1调控的T-bet分子的表达。刺激的。重要的是,与慢性感染的对照Gag-T_(EXO / Null)疫苗相比,Gag-T_(EXO / IL21)疫苗可诱导针对已建立的表达Gag的BL6-10_(Gag)黑色素瘤肺转移瘤更强的Gag特异性治疗免疫。因此,这项研究对开发用于慢性感染患者的新型治疗性疫苗应具有重大影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号